Patients and caregivers dealing with first recurrence glioblastoma are being sought for an important survey. Make your voice heard.

Jenn Ortiz, a two-time brain tumor survivor, describes her participation in the Patient Reported Outcomes rGBM study.

Gleolan Brain Dye, imaging agent, helps neurosurgeons to see “high grade gliomas” during surgery. Learn about Gleolan.

Northwest Biotherapeutics has applied for approval to market DCVax®, a personalized immune therapy, for the treatment of Glioblastoma.

We are looking for Glioblastoma (GBM) patients and their caregivers to participate in an important study on recurrent GBM.

We are looking to interview patients, and their caregivers, who are living with recurrent glioblastoma (GBM).

Glioblastoma overview with a description of the symptoms of this treatment-resistant brain cancer.

Jennifer Ortiz Is the 1st runner-up recipient of the 2023 EBCI National HOPE Award.

Thanks to Kiyatec’s 3D Predict, cancer patients with elevated HCG levels and their physicians are seeing game-changing results.

Imvax is conducting a new phase 2b clinical study, with a combination immunotherapy, for newly diagnosed patients with glioblastoma.

The Pacific Neuroscience Institute has created a series of videos featuring patients and caregivers discussing brain tumor treatments.

If you have been diagnosed with rGBM (first recurrence only), would you like to participate in a PAID short interview?